Skip to main content

Table 3 Study sites with day 3 parasite positivity rate (PPR) >3 %

From: Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data

Study site (country)

Year

Treatment

Day 3 PPR (95 % CI)a

New Halfa (Sudan)

2006

AL

3.0 % (1/33) (0.5–15.3)

ELWA Hospital (Liberia)

2007

AL

3.4 % (2/58) (0.9–11.7)

JFK Hospital (Liberia)

2007

AL

3.8 % (2/53) (1.0–12.8)

Bagamoyo (Tanzania)

2004

AL

4.0 % (2/50) (1.1–13.5)

Afokang (Nigeria)

2007–08

AL

5.9 % (10/170) (3.2–10.5)

Ndumo (South Africa)

2002

AL

6.0 % (6/100) (2.8–12.5)

San Pedro (Côte d’Ivoire)

2012

AL

6.5 % (2/31) (1.8–20.7)

Gedaref (Sudan)

2006

AL

7.8 % (4/51) (3.1–18.5)

Andapa (Madagascar)

2007

AS-AQ (loose NFDC)

3.3 % (1/30) (0.6–16.7)

Gaya (Niger)

2011

AS-AQ (FDC)

3.9 % (3/77) (1.3–10.8)

Grand Gedeh County (Liberia)

2010–11

AS-AQ (FDC)

3.9 % (4/102) (1.5–9.7)

Dabola (Guinea)

2004

AS-AQ (loose NFDC)

4.5 % (5/110) (1.9–10.2)

Afokang (Nigeria)

2007–08

AS-AQ (FDC)

5.2 % (9/173) (2.8–9.6)

Malakal (Sudan)

2003

AS-AQ (loose NFDC)

5.3 % (7/131) (2.6–10.6)

Kuito (Angola)

2003

AS-AQ (loose NFDC)

5.4 % (5/93) (2.3–11.9)

Kailahun (Sierra Leone)

2004

AS-AQ (loose NFDC)

5.6 % (7/125) (2.7–11.1)

Mlomp (Senegal)

1999

AS-AQ (loose NFDC)

5.8 % (9/154) (3.1–10.7)

Richard Toll (Senegal)

2003

AS-AQ (loose NFDC)

7.1 % (3/42) (2.5–19.0)

Miandrivazo (Madagascar)

2006

AS-AQ (loose NFDC)

10.3 % (7/68) (5.1–19.8)b

Yaoundé (Cameroon)

2005

AS-AQ (coblistered NFDC)

30.7 % (31/101) (22.5–40.3)b

Manhiça (Mozambique)

2005–06

DP

4.0 % (12/299) (2.3–6.9)

Afokang (Nigeria)

2007–08

DP

7.7 % (11/142) (4.4–13.3)

  1. aAssociated 95 % confidence interval computed using Wilson’s method; bthese sites have day 3 PPR >10 % and would be classed as sites with suspected partial artemisinin resistance requiring further investigation. Patients in Miandrivazo were treated with ASAQ-loose NFDC and those in Yaoundé treated with ASAQ-coblistered NFDC. AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; NFDC, non-fixed dose combination; PPR, parasite positivity rate